Biognosys launches groundbreaking P2 Plasma Enrichment technology for unbiased, deep plasma proteomics at ASMS 2024
30 Maio 2024 - 10:15AM
Biognosys, a leader in next-generation proteomics services,
software and kits for life sciences research and drug development,
today announced the launch of the novel, proprietary P2 Plasma
Enrichment method for single-well, single particle-type enrichment
with market leading performance and sensible, superior economics.
P2-based plasma proteomics can be used for human or for
animal-model proteomics studies and clinical research.
This novel P2 plasma proteomics method achieves a
proteome coverage of 7,000 proteins in a previously published
five-cancer plasma sample set, demonstrating highest
reproducibility, unprecedented enrichment of low abundant proteins,
and unparalleled throughput on Bruker timsTOF® HT mass
spectrometers. The technical features and performance data will be
presented at the American Society of Mass Spectrometry (ASMS)
Annual Conference in Anaheim, CA on Monday, June 3rd during
Biognosys’ Breakfast Seminar, “Accelerating Drug Discovery and
Development with Biognosys’ Next-Generation Proteomics
Services,” and on Wednesday, June 5th during the WP 084 poster
session.
“With our proprietary P2 Plasma Enrichment method,
Biognosys can now significantly enhance the depth and throughput in
plasma proteomics beyond what existing methods could achieve,”
explains Dr. Oliver Rinner, CEO and founder of Biognosys. “Most
importantly, this advancement comes with exceptional
reproducibility, which is crucial for quantitative studies. It also
provides superior economics and achieves a false discovery rate of
less than 1%, that cannot be matched with expensive, high-plex
affinity-based methods. Additionally, our optional licensing model
now also opens a new avenue for advanced proteomics mass
spectrometry end-users to access our cutting-edge methods and
software for in-house use.”
Dr. Rohan Thakur, President Bruker LSMS Division,
says: “Biognosys' state-of-the-art P2 Plasma method enables
profiling of the plasma proteome with rigor, providing deep
insights into protein expression, and uniquely leverages the proven
robustness of the timsTOF HT. A powerful combination that will
provide superior data-completeness with simplicity, both of
significant value for large cohort studies.”
Biognosys’ P2 Plasma Proteomics enrichment method
is based on a proprietary, single-well, single particle-type
workflow that combines optimized surface chemistry with a novel
buffer system that stabilizes the labile protein corona that forms
around particles in blood plasma. P2 enriches low abundant proteins
in the soft-corona layer while effectively deriching abundant
plasma proteins. This approach works in single-well format which
benefits throughput and quantitative reproducibility. P2 provides
both, exceptional depth, and a low false discovery rate at a cost
per sample that is significantly lower compared to affinity-based
high-plex proteomics systems. Additionally, P2 achieves higher data
quality compared to affinity-based methods, which inevitably suffer
from epitope cross-talk issues.
The P2 method achieves the highest ever reported
plasma enrichment with a 10-fold factor of enrichment compared to
untreated plasma on a Bruker timsTOF® HT platform with the 4D
dia-PASEF method, and data processing with Spectronaut 19. This
latest version of Spectronaut has now been extensively trained and
optimized for timsTOF platform MS/MS data. Thanks to the use of
short 17-minute LC-gradients on the Bruker timsTOF® HT platform,
the P2 method opens new possibilities for mid-to-large-scale and
population health discovery studies with depth at affordable
economics.
The P2 Plasma Enrichment method will be available
as a contract research service from Biognosys’ facilities in
Schlieren, Zurich in Switzerland and in Newton, Massachusetts in
the United States, through the TrueDiscovery unbiased proteomics
platform. For end-users of facilities equipped with timsTOF HT or
other highest-performance mass spectrometry platforms, the method
is now also available as a licensing option for in-house use.
Under a previously announced strategic partnership
of Biognosys and Alamar Biosciences, Biognosys will now also offer
the optional combination of P2-based mass spectrometry plasma
proteomics with Alamar’s targeted, mid-plex ultra-high sensitivity
NULISA proteomics panels. This integrated, complementary approach
enables the most quantitative and complete access to the plasma
proteome by combining deep unbiased DIA-MS discovery proteomics
with highly specific and ultra-sensitive mid- and high-plex Alamar
NULISA assays for low-abundance proteins such as cytokines,
chemokines and important disease protein biomarkers from plasma for
inflammation of central nervous systems disease research.
About
TrueDiscovery®
The Biognosys TrueDiscovery platform offers
integrated proteomics solutions across the entire drug development
pipeline.
TrueDiscovery is powered by Hyper Reaction
Monitoring (HRM) mass spectrometry, an advanced Data Independent
Acquisition (DIA)-based protein quantification technology
co-invented and patented by Biognosys.
TrueDiscovery is the only platform that searches
the complete proteome to quantify thousands of the most relevant
proteins, including an unlimited number of proteoforms. The
platform enables the deepest unbiased profiling of tissue and
biofluids proteomes with unbeatable specificity on a large scale.
The generated data are highly reproducible and easily transferrable
to clinical assays. Studies can be performed in a GCP compliant
environment. For more information, visit truediscovery.bio.
About Biognosys
At Biognosys, we believe that deep proteome
insights hold the key to breakthrough discoveries that transform
science for better lives. With our versatile portfolio of
next-generation proteomics solutions, including the TrueDiscovery®,
TrueTarget®, and TrueSignature® research service platforms, our
flagship software Spectronaut®, and the PQ500™ kit, we make the
proteome actionable to empower research, drug development, and
clinical decision-making. Our solutions provide a multi-dimensional
view of protein expression, function, and structure in all
biological species and sample types. Our unique, patented
technologies utilize high-resolution mass spectrometry to quantify
thousands of proteins with industry-leading precision, depth, and
throughput. Through our strategic partnership with Bruker (Nasdaq:
BRKR), we make proteomics globally accessible. For more
information, visit biognosys.com.
A photo accompanying this announcement is available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/54e3490e-7093-4c13-8083-05c27cf968a5
Media Contact
Yves Serroen
Head of Marketing and Communications
Phone +41 (0) 44 244 50 07
yves.serroen@biognosys.com
Bruker (NASDAQ:BRKR)
Gráfico Histórico do Ativo
De Jun 2024 até Jul 2024
Bruker (NASDAQ:BRKR)
Gráfico Histórico do Ativo
De Jul 2023 até Jul 2024